Hirmas Nader相关文献与解析，生知库 | 链接生命科学的每一步

Gremke Niklas, Besong Isabelle, Stroh Alina, von Wichert Luise, Witt Marie, ElmshÃ¤user Sabrina, Wanzel Michael, Fromm Martin F, Taudte R Verena, Schmatloch Sabine, Karn Thomas, Reinisch Mattea, Hirmas Nader, Loibl Sibylle, WÃ¼ndisch Thomas, Litmeyer Anne-Sophie, Jank Paul, Denkert Carsten, Griewing Sebastian, Wagner Uwe, Stiewe Thorsten

代谢

乳腺癌

PI3K/Akt

肿瘤免疫

发表日期：2025

文献求助收藏

Shifting the Paradigm: The Transformative Role of Neoadjuvant Therapy in Early Breast Cancer

范式转变：新辅助疗法在早期乳腺癌治疗中的变革性作用

期刊:Cancers

影响因子:4.4

doi:10.3390/cancers16183236

Hirmas, Nader; Holtschmidt, Johannes; Loibl, Sibylle

Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial)

前列腺特异性膜抗原 PET/CT 在预后不良的中高危前列腺癌根治性放射治疗前的随机试验 (PSMA-dRT 试验)

期刊:

影响因子:

doi:10.2967/jnumed.123.267004

Nikitas, John; Lam, Ethan; Booker, Kiara Adame; Fendler, Wolfgang P; Eiber, Matthias; Hadaschik, Boris; Herrmann, Ken; Hirmas, Nader; Lanzafame, Helena; Stuschke, Martin; Czernin, Johannes; Steinberg, Michael L; Nickols, Nicholas G; Kishan, Amar U; Calais, Jeremie

Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial (AMICA)

一线化疗后，采用 CDK4/6 抑制剂 ribociclib 进行抗激素维持治疗治疗激素受体阳性/HER2 阴性转移性乳腺癌：一项 II 期试验 (AMICA)

期刊:Breast

影响因子:7.9

doi:10.1016/j.breast.2023.08.007

Decker, Thomas; Lüdtke-Heckenkamp, Kerstin; Melnichuk, Luidmila; Hirmas, Nader; Lübbe, Kristina; Zahn, Mark-Oliver; Schmidt, Marcus; Denkert, Carsten; Lorenz, Ralf; Müller, Volkmar; Zahm, Dirk-Michael; Mundhenke, Christoph; Bauer, Stefan; Thill, Marc; Seropian, Peter; Filmann, Natalie; Loibl, Sibylle

Predictive value of highly sensitive basal versus stimulated thyroglobulin measurement in long-term follow-up of thyroid cancer

高灵敏度基础甲状腺球蛋白与刺激后甲状腺球蛋白测定在甲状腺癌长期随访中的预测价值

期刊:Endocrine Connections

影响因子:2.8

doi:10.1530/EC-22-0312

Pabst, Kim Magaly; Seifert, Robert; Hirmas, Nader; Broecker-Preuss, Martina; Weber, Manuel; Peter Fendler, Wolfgang; Bartel, Timo; Theurer, Sarah; Herrmann, Ken; Görges, Rainer

(68)Ga-FAPI as a Diagnostic Tool in Sarcoma: Data from the (68)Ga-FAPI PET Prospective Observational Trial

(68)Ga-FAPI 作为肉瘤诊断工具：来自 (68)Ga-FAPI PET 前瞻性观察试验的数据

期刊:

影响因子:

doi:10.2967/jnumed.121.262096

Kessler, Lukas; Ferdinandus, Justin; Hirmas, Nader; Bauer, Sebastian; Dirksen, Uta; Zarrad, Fadi; Nader, Michael; Chodyla, Michal; Milosevic, Aleksandar; Umutlu, Lale; Schuler, Martin; Podleska, Lars Erik; Schildhaus, Hans-Ulrich; Fendler, Wolfgang P; Hamacher, Rainer

FAP

发表日期：2022

文献求助收藏

Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol

PSMA PET/CT 在根治性放疗前用于预后不良的中危或高危前列腺癌的 III 期多中心随机试验 [PSMA dRT]：研究方案

期刊:BMC Cancer

影响因子:3.4

doi:10.1186/s12885-021-08026-w

Calais, Jeremie; Zhu, Shaojun; Hirmas, Nader; Eiber, Matthias; Hadaschik, Boris; Stuschke, Martin; Herrmann, Ken; Czernin, Johannes; Kishan, Amar U; Nickols, Nicholas G; Elashoff, David; Fendler, Wolfgang P

Impact of (18)F-FDG PET/CT, CT and EBUS/TBNA on preoperative mediastinal nodal staging of NSCLC

(18)F-FDG PET/CT、CT 和 EBUS/TBNA 对非小细胞肺癌术前纵隔淋巴结分期的影响

期刊:BMC Medical Imaging

影响因子:3.2

doi:10.1186/s12880-021-00580-w

Al-Ibraheem, Akram; Hirmas, Nader; Fanti, Stefano; Paez, Diana; Abuhijla, Fawzi; Al-Rimawi, Dalia; Al-Rasheed, Ula; Abdeljalil, Riad; Hawari, Feras; Alrabi, Kamal; Mansour, Asem

Molecular Subgroup Is the Strongest Predictor of Medulloblastoma Outcome in a Resource-Limited Country

在资源匮乏的国家，分子亚型是髓母细胞瘤预后的最强预测因子

期刊:JCO Global Oncology

影响因子:3

doi:10.1200/GO.21.00127

Amayiri, Nisreen; Swaidan, Maisa; Ibrahimi, Ahmed; Hirmas, Nader; Musharbash, Awni; Bouffet, Eric; Al-Hussaini, Maysa; Ramaswamy, Vijay

细胞生物学

发表日期：2021

文献求助收藏

Challenges and strategies for delivering effective breast cancer care in conflict zones

在冲突地区提供有效乳腺癌治疗的挑战和策略

Targeting PI3K inhibitor resistance in breast cancer with metabolic drugs.

利用代谢药物靶向治疗乳腺癌中的PI3K抑制剂耐药性

Shifting the Paradigm: The Transformative Role of Neoadjuvant Therapy in Early Breast Cancer

范式转变：新辅助疗法在早期乳腺癌治疗中的变革性作用

Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial)

前列腺特异性膜抗原 PET/CT 在预后不良的中高危前列腺癌根治性放射治疗前的随机试验 (PSMA-dRT 试验)

Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial (AMICA)

一线化疗后，采用 CDK4/6 抑制剂 ribociclib 进行抗激素维持治疗治疗激素受体阳性/HER2 阴性转移性乳腺癌：一项 II 期试验 (AMICA)

Predictive value of highly sensitive basal versus stimulated thyroglobulin measurement in long-term follow-up of thyroid cancer

高灵敏度基础甲状腺球蛋白与刺激后甲状腺球蛋白测定在甲状腺癌长期随访中的预测价值

(68)Ga-FAPI as a Diagnostic Tool in Sarcoma: Data from the (68)Ga-FAPI PET Prospective Observational Trial

(68)Ga-FAPI 作为肉瘤诊断工具：来自 (68)Ga-FAPI PET 前瞻性观察试验的数据

Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol

PSMA PET/CT 在根治性放疗前用于预后不良的中危或高危前列腺癌的 III 期多中心随机试验 [PSMA dRT]：研究方案

Impact of (18)F-FDG PET/CT, CT and EBUS/TBNA on preoperative mediastinal nodal staging of NSCLC

(18)F-FDG PET/CT、CT 和 EBUS/TBNA 对非小细胞肺癌术前纵隔淋巴结分期的影响

Molecular Subgroup Is the Strongest Predictor of Medulloblastoma Outcome in a Resource-Limited Country

在资源匮乏的国家，分子亚型是髓母细胞瘤预后的最强预测因子